radioligand therapy

You have access
PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study
Caner Civan, Stefan Kasper, Christoph Berliner, Pedro Fragoso-Costa, Viktor Grünwald, Michael Pogorzelski, Benedikt Michael Schaarschmidt, Stephan Lang, David Kersting, Michael Nader, Katharina Lückerath, Ken Herrmann, Wolfgang P. Fendler and Manuel Weber

Journal of Nuclear Medicine September 22, 2022, jnumed.122.264342; DOI: https://doi.org/10.2967/jnumed.122.264342
You have access
Effects of ²²⁵Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
Dong Yun Lee and Yong-il Kim

Journal of Nuclear Medicine June 1, 2022, 63 (6) 840-846; DOI: https://doi.org/10.2967/jnumed.121.262017
You have access
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?
Andrei Gafita, Hui Wang, Andrew Robertson, Wesley R. Armstrong, Raphael Zaum, Manuel Weber, Farid Yagubbayli, Clemens Kratochwil, Tristan R. Grogan, Kathleen Nguyen, Fernando Navarro, Rouzbeh Esfandiari, Isabel Rauscher, Bjoern Menze, David Elashoff, Ebrahim S. Delpassand, Ken Herrmann, Johannes Czernin, Michael S. Hofman, Jeremie Calais, Wolfgang P. Fendler and Matthias Eiber

Journal of Nuclear Medicine February 1, 2022, 63 (2) 226-232; DOI: https://doi.org/10.2967/jnumed.121.261906
You have access
Kidney Doses in ¹⁷⁷Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf

Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245
Open Access
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer
Alexander Wurzer, Jan-Philip Kunert, Sebastian Fischer, Veronika Felber, Roswitha Beck, Francesco De Rose, Calogero D'Alessandria, Wolfgang Andreas Weber and Hans-Jürgen Wester

Journal of Nuclear Medicine January 27, 2022, jnumed.121.263371; DOI: https://doi.org/10.2967/jnumed.121.263371
You have access
Assessing Response to ¹⁷⁷Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
Kerstin Michalski, Claudius Klein, Tonio Brüggemann, Philipp T. Meyer, Cordula A. Jilg and Juri Ruf

Journal of Nuclear Medicine December 1, 2021, 62 (12) 1741-1746; DOI: https://doi.org/10.2967/jnumed.120.260836
You have access
Landscape Analysis of Phase 2 and 3 Clinical Trials for Targeted Radionuclide Therapy
Erik Mittra and Lisa Bodei

Journal of Nuclear Medicine August 1, 2021, 62 (8) 1031-1032; DOI: https://doi.org/10.2967/jnumed.120.258103
You have access
First Clinical Results for PSMA-Targeted α-Therapy Using ²²⁵Ac-PSMA-I&T in Advanced-mCRPC Patients
Mathias Johannes Zacherl, Franz Josef Gildehaus, Lena Mittlmeier, Guido Böning, Astrid Gosewisch, Vera Wenter, Marcus Unterrainer, Nina Schmidt-Hegemann, Claus Belka, Alexander Kretschmer, Jozefina Casuscelli, Christian G. Stief, Marcus Unterrainer, Peter Bartenstein, Andrei Todica and Harun Ilhan

Journal of Nuclear Medicine May 10, 2021, 62 (5) 669-674; DOI: https://doi.org/10.2967/jnumed.120.251017
You have access
¹⁷⁷Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
Hsiou-Ting Kuo, Kuo-Shyan Lin, Zhengxing Zhang, Carlos F. Uribe, Helen Merkens, Chengcheng Zhang and François Bénard

Journal of Nuclear Medicine April 1, 2021, 62 (4) 521-527; DOI: https://doi.org/10.2967/jnumed.120.250738
You have access
¹⁷⁷Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu and Xiaoyuan Chen

Journal of Nuclear Medicine December 1, 2020, 61 (12) 1772-1778; DOI: https://doi.org/10.2967/jnumed.120.242263

Main menu

User menu

Search

radioligand therapy

Pages